A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Oxaliplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Diagnosis of primary cancer of the colon or rectum

• Must have measurable disease

• Must be able to comply with study procedure

Exclusion Criteria:

• Prior chemotherapy for advanced disease

• Pregnancy or lactation

• Candidates for surgical resection of one or more metastatic foci

• Second primary cancer

• Inability to take folic acid or vitamin B12